FINWIRES · TerminalLIVE
FINWIRES

Cettire to Expand China Footprint With Planned Launch on TMall Global

By

Cettire (ASX:CTT) said it will broaden its global footprint through the launch of a flagship store on TMall Global, Alibaba Group's cross-border e-commerce platform, marking its entry into mainland China, according to an Australian bourse filing on May 29 after market hours.

The move complements the company's existing presence on JD.com and its direct-to-consumer platform cettire.cn, launched in June 2024, per the filing.

The company will continue using its proprietary technology and global supply chain for fulfillment without maintaining local inventory, with the TMall Global launch contingent on completing technology integration expected in the first quarter of fiscal 2027, the filing added.

Related Articles

Asia

Downer EDI Buys Back Nearly 111,000 Ordinary Shares

Downer EDI (ASX:DOW, NZE:DOW) repurchased 110,870 ordinary shares on May 29 for AU$900,120 in total as part of an on-market buyback, according to a Monday filing with the Australian bourse.The company plans to repurchase up to 33.6 million of its ordinary shares, the filing said.

$ASX:DOW$NZE:DOW
Asia

Rio Tinto Group Begins Commissioning Nearly $2 Billion AP60 Smelter Expansion in Canada

Rio Tinto Group (ASX:RIO) started commissioning its $1.5 billion AP60 aluminum smelter expansion at Complexe Arvida in Quebec, with start-up work having commenced in March and full 96-pot operations targeted for completion by the end of year, the company said on May 29 after hours.The project will increase AP60's annual aluminum capacity by about 160,000 tonnes to around 220,000 tonnes while replacing output from older Arvida potrooms scheduled for closure in June.The expansion is expected to support about 100 permanent jobs, generate over 1,500 construction jobs, and contribute more than $1 billion in economic benefits to Quebec.

$ASX:RIO
Asia

Genrix Grants CQ Pharmaceutical Distribution Rights for Myeloma Drug in China, Hong Kong, Macau, Taiwan

Chongqing Genrix Biopharmaceutical (SHA:688443) granted C.Q. Pharmaceutical (SHE:000950) subsidiary Yaoyou Pharmaceutical exclusive development and distribution rights for the GR1803 drug across China and Hong Kong, Macau, and Taiwan.The agreement covers development such as clinical trials, research, and manufacturing, as well as sales, the filing said.The GR1803 velitumimumab drug is indicated for multiple myeloma, a rare form of blood cancer.Yaoyou will pay Genrix up to 600 million yuan in initial payment, listing milestone, and technology transfer milestone payments.Genrix will also be eligible to receive sales royalties of up to a minimum percentage of two digits.

$SHA:688443$SHE:000950